{"public_id":"cl_8725573026ae54c9e6a72b3f4b524e71","status":"active","superseded_by_public_id":null,"corpus_id":9880383,"text":"Alterations associated with sensitivity to PI3K/AKT/mTOR, CDK, and HER2/EGFR inhibitors were detected in brain metastases, indicating that primary biopsies alone may miss opportunities for targeted therapy.","confidence":0.96,"paper":{"corpus_id":9880383,"title":"Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.","url":"https://sah.borca.ai/papers/9880383"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.96,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_d30f81b7f6ac73e5c0b242631c8b418f","name":"PI3K/AKT/mTOR inhibitors","description":"Targeted drugs that inhibit the PI3K/AKT/mTOR signaling pathway.","types":["therapeutic class"],"url":"https://sah.borca.ai/concepts/co_d30f81b7f6ac73e5c0b242631c8b418f"},{"public_id":"co_f57e19502992343215fa004b9da2899c","name":"brain metastases","description":"Secondary tumors that have spread to the brain from a primary cancer site.","types":["condition"],"url":"https://sah.borca.ai/concepts/co_f57e19502992343215fa004b9da2899c"},{"public_id":"co_f677120f01da030121e984530e22b939","name":"CDK inhibitors","description":"Targeted drugs that inhibit cyclin-dependent kinases.","types":["therapeutic class"],"url":"https://sah.borca.ai/concepts/co_f677120f01da030121e984530e22b939"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_8725573026ae54c9e6a72b3f4b524e71"}